Trials / Recruiting
RecruitingNCT07082803
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Treeline Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLN-121 | Specified dose on specified days. |
| DRUG | TLN-254 | Specified dose on specified days. |
| DRUG | TLN-121 | Specified dose on specified days. |
Timeline
- Start date
- 2025-06-23
- Primary completion
- 2030-09-01
- Completion
- 2030-11-01
- First posted
- 2025-07-24
- Last updated
- 2026-03-27
Locations
12 sites across 3 countries: United States, Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07082803. Inclusion in this directory is not an endorsement.